Skip to content

US · SXTC

China SXT Pharmaceuticals, Inc.

Sector
Healthcare · Drug Manufacturers - Specialty & Generic
Headquarters
Taizhou, JS 225300

Price · as of 2026-10-31

$3.25

Market cap 45.55K

Price history

The price history chart is shown only to users with a Pro subscription.

InvestorsCraft valuation

Fair value (AI, DCF / IC, Graham) for China SXT Pharmaceuticals, Inc. (SXTC) is available to Pro members and via the machine API.

  • AI valuation — available
  • Intrinsic / IC value — available
  • Upside vs price — available

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

The valuation history chart is shown only to users with a Pro subscription.

Historic valuation ratios

Pick a category, then toggle metrics to compare.

Historic valuation ratios are shown only to users with a Pro subscription.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About China SXT Pharmaceuticals, Inc.

        China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

        CEO
        Feng Zhou
        Employees
        56
        Beta
        1.82

        Peer comparison

        Same-industry comparables, ranked by market cap.

        The peer comparison table is shown only to users with a Pro subscription.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice.